首页> 外文期刊>British journal of ophthalmology >Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection.
【24h】

Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection.

机译:溴莫尼定治疗后原发性开角型青光眼的对比敏感性得到改善:这是神经保护的一种情况。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. METHODS: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. RESULTS: IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters. CONCLUSION: Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.
机译:目的:确定在青光眼中开始溴莫尼定治疗后的视觉结果。方法:将16例新诊断,先前未接受治疗的青光眼患者随机分配为timolol 0.5%或溴莫尼定0.2%。在基线和3个月后评估视力,对比敏感度(CS),视野,眼内压(IOP),血压和心率。结果:两组的眼压降低相似(p <0.05)。溴莫尼定改善CS;在右眼6和12 cpd时(p = 0.043,p = 0.017);在左眼3和12 cpd(p = 0.044,p = 0.046)。右眼在18 cpd时Timolol降低CS(p = 0.041)。其他任何测量参数均无变化。结论:青光眼患者在溴莫尼定治疗开始后表现出改善的CS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号